Abstract | OBJECTIVE: Neonatal coronary thrombosis is a rarely reported disorder, with variable outcomes described. This study assessed the feasibility and safety of an institutional protocol using tissue plasminogen activator (tPA) administration for the treatment of neonatal coronary artery thrombi. METHODS: RESULTS: The three described cases presented at 5 hours, 15 hours, and 10 days of life. The patients identified underwent the tPA protocol at least once. There was clinical evidence of improvement in coronary flow, as well as demonstration of increased left ventricular function and decreased mitral regurgitation. No major adverse events occurred. CONCLUSION:
|
Authors | Delaram Molkara, Jose A Silva Sepulveda, Thomas Do, Christopher Davis, Gregory P Goldstein, John W Moore, Howaida G El-Said |
Journal | Congenital heart disease
(Congenit Heart Dis)
Vol. 12
Issue 3
Pg. 270-274
(May 2017)
ISSN: 1747-0803 [Electronic] United States |
PMID | 28140523
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | © 2017 Wiley Periodicals, Inc. |
Chemical References |
- Fibrinolytic Agents
- Tissue Plasminogen Activator
|
Topics |
- Cardiac Catheterization
- Coronary Angiography
- Coronary Thrombosis
(complications, diagnosis, drug therapy)
- Dose-Response Relationship, Drug
- Echocardiography
- Electrocardiography
- Female
- Fibrinolytic Agents
(administration & dosage)
- Humans
- Infant, Newborn
- Male
- Mitral Valve Insufficiency
(diagnosis, etiology, physiopathology)
- Thrombolytic Therapy
(methods)
- Tissue Plasminogen Activator
(administration & dosage)
- Ventricular Dysfunction, Left
(diagnosis, etiology, physiopathology)
- Ventricular Function, Left
(physiology)
|